AU2019355870B2 - Thieno[3,2-b]pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use - Google Patents

Thieno[3,2-b]pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use Download PDF

Info

Publication number
AU2019355870B2
AU2019355870B2 AU2019355870A AU2019355870A AU2019355870B2 AU 2019355870 B2 AU2019355870 B2 AU 2019355870B2 AU 2019355870 A AU2019355870 A AU 2019355870A AU 2019355870 A AU2019355870 A AU 2019355870A AU 2019355870 B2 AU2019355870 B2 AU 2019355870B2
Authority
AU
Australia
Prior art keywords
thieno
trifluoromethyl
pyridin
methylcarbamoyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019355870A
Other languages
English (en)
Other versions
AU2019355870A1 (en
Inventor
Michael Angelastro
Robert H. Barker Jr.
Yong-Mi Choi
Mary A. Cromwell
Bradford Hirth
John Jiang
Sungtaek Lim
Elina MAKINO
Sachin MANIAR
Mark Munson
Kwon Yon Musick
James Pribish
Sukanthini Thurairatnam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2019355870A1 publication Critical patent/AU2019355870A1/en
Application granted granted Critical
Publication of AU2019355870B2 publication Critical patent/AU2019355870B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019355870A 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use Active AU2019355870B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862739405P 2018-10-01 2018-10-01
US62/739,405 2018-10-01
PCT/US2019/054085 WO2020072504A1 (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Publications (2)

Publication Number Publication Date
AU2019355870A1 AU2019355870A1 (en) 2021-05-20
AU2019355870B2 true AU2019355870B2 (en) 2023-11-16

Family

ID=68296740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019355870A Active AU2019355870B2 (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use

Country Status (15)

Country Link
US (1) US11098056B2 (cg-RX-API-DMAC7.html)
EP (1) EP3861000A1 (cg-RX-API-DMAC7.html)
JP (1) JP7545979B2 (cg-RX-API-DMAC7.html)
KR (1) KR102903997B1 (cg-RX-API-DMAC7.html)
CN (1) CN113423711B (cg-RX-API-DMAC7.html)
AU (1) AU2019355870B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005914A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114722A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005738A2 (cg-RX-API-DMAC7.html)
IL (1) IL281811B2 (cg-RX-API-DMAC7.html)
MA (1) MA53043B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003794A (cg-RX-API-DMAC7.html)
SG (1) SG11202102987VA (cg-RX-API-DMAC7.html)
TW (1) TWI821426B (cg-RX-API-DMAC7.html)
WO (1) WO2020072504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
EP4483954A1 (en) * 2023-06-29 2025-01-01 Masarykova Univerzita Substituted thieno [3,2-b]pyridines as inhibitors of protein kinases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
WO2001010842A2 (en) * 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2009062258A1 (en) * 2007-11-15 2009-05-22 Cytopia Research Pty Ltd N-containing heterocyclic compounds
WO2017112777A1 (en) * 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017192930A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2018237084A1 (en) * 2017-06-21 2018-12-27 SHY Therapeutics LLC COMPOUNDS INTERACTING WITH RAS SUPERFAMIL FOR USE IN THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES AND FIBROTIC DISEASES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
FR2821356A1 (fr) * 2001-02-23 2002-08-30 Cerep Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
AU2010210426B2 (en) * 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
KR20130131461A (ko) * 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
CA3199430A1 (en) * 2015-01-16 2016-07-21 The General Hospital Corporation Compounds for improving mrna splicing
CA3025943A1 (en) 2016-06-10 2017-12-14 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
KR20190070972A (ko) * 2016-11-02 2019-06-21 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 유도체
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
BR112019023109A2 (pt) 2017-05-04 2020-05-26 Glenmark Pharmaceuticals S.A. Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
WO2001010842A2 (en) * 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2009062258A1 (en) * 2007-11-15 2009-05-22 Cytopia Research Pty Ltd N-containing heterocyclic compounds
WO2017112777A1 (en) * 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017192930A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2018237084A1 (en) * 2017-06-21 2018-12-27 SHY Therapeutics LLC COMPOUNDS INTERACTING WITH RAS SUPERFAMIL FOR USE IN THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES AND FIBROTIC DISEASES

Also Published As

Publication number Publication date
AU2019355870A1 (en) 2021-05-20
TWI821426B (zh) 2023-11-11
CO2021005738A2 (es) 2021-05-10
MX2021003794A (es) 2021-09-08
US11098056B2 (en) 2021-08-24
TW202035419A (zh) 2020-10-01
JP2022508523A (ja) 2022-01-19
JP7545979B2 (ja) 2024-09-05
CN113423711A (zh) 2021-09-21
KR102903997B1 (ko) 2025-12-26
BR112021005914A2 (pt) 2021-06-29
CN113423711B (zh) 2024-03-15
IL281811B1 (en) 2024-11-01
WO2020072504A1 (en) 2020-04-09
MA53043A1 (fr) 2022-08-31
US20200102324A1 (en) 2020-04-02
MA53043B2 (fr) 2024-05-31
EP3861000A1 (en) 2021-08-11
SG11202102987VA (en) 2021-04-29
CA3114722A1 (en) 2020-04-09
IL281811A (en) 2021-05-31
IL281811B2 (en) 2025-03-01
KR20210087033A (ko) 2021-07-09

Similar Documents

Publication Publication Date Title
US10988478B1 (en) Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
EP3359541B1 (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US9273057B2 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
ES2548532T3 (es) Compuestos de pirrolopirimidina como inhibidores de CDK4/6
KR20220016049A (ko) Btk 억제제 고리 유도체, 이의 제조 방법 및 이의 약제학적 응용
TW202334138A (zh) 癌症治療方法
KR20230028269A (ko) 헌팅턴병을 치료하기 위한 htt 조절제
KR20190040319A (ko) N-(피리딘-2-일)피리딘-술폰아미드 유도체 및 질환의 치료에서 이들의 용도
CN116783199A (zh) 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物
WO2020048605A1 (en) Novel pyrrolidine amine compounds for the treatment of autoimmune disease
US20240109917A1 (en) Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
ES3023544T3 (en) Atm kinase inhibitors and compositions and methods of use thereof
KR102903997B1 (ko) UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법
RU2810928C2 (ru) Ингибиторы уридин-5-дифосфат (udp) гликозилтрансферазы и способы их применения
HK40082036B (en) Atm kinase inhibitors and compositions and methods of use thereof
HK40082036A (en) Atm kinase inhibitors and compositions and methods of use thereof
EP4506349A2 (en) Tetrahydrothieno pyridine derivatives as ddrs inhibitors
HK40053673B (en) Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
HK40043697A (en) Novel pyrrolidine amine compounds for the treatment of autoimmune disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)